IL256237B - Solid forms of (z) - 4 - (5 - ((3 - benzyl - 4 - oxo - 2 - thioxothiazolidine - 5 - ylidin) methyl) furan - 2 - yl) benzoic acid - Google Patents
Solid forms of (z) - 4 - (5 - ((3 - benzyl - 4 - oxo - 2 - thioxothiazolidine - 5 - ylidin) methyl) furan - 2 - yl) benzoic acidInfo
- Publication number
- IL256237B IL256237B IL256237A IL25623717A IL256237B IL 256237 B IL256237 B IL 256237B IL 256237 A IL256237 A IL 256237A IL 25623717 A IL25623717 A IL 25623717A IL 256237 B IL256237 B IL 256237B
- Authority
- IL
- Israel
- Prior art keywords
- thioxothiazolidin
- ylidene
- furan
- oxo
- benzyl
- Prior art date
Links
- AEZGRQSLKVNPCI-UNOMPAQXSA-N 4-[5-[(z)-(3-benzyl-4-oxo-2-sulfanylidene-1,3-thiazolidin-5-ylidene)methyl]furan-2-yl]benzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1C(O1)=CC=C1\C=C/1C(=O)N(CC=2C=CC=CC=2)C(=S)S\1 AEZGRQSLKVNPCI-UNOMPAQXSA-N 0.000 title 1
- 239000007787 solid Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
- C07C215/02—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C215/04—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated
- C07C215/06—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic
- C07C215/08—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic with only one hydroxy group and one amino group bound to the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
- C07C215/02—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C215/04—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated
- C07C215/06—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic
- C07C215/10—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic with one amino group and at least two hydroxy groups bound to the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
- C07C215/02—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C215/40—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton with quaternised nitrogen atoms bound to carbon atoms of the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562175066P | 2015-06-12 | 2015-06-12 | |
| US201662275655P | 2016-01-06 | 2016-01-06 | |
| PCT/US2016/037067 WO2016201356A1 (en) | 2015-06-12 | 2016-06-10 | Solid forms of (z)-4-(5-((3-benzyl-4-oxo-2-thioxothiazolidin-5-ylidene)methyl)furan-2-yl)benzoic acid |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL256237A IL256237A (en) | 2018-02-28 |
| IL256237B true IL256237B (en) | 2021-12-01 |
Family
ID=57504544
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL256237A IL256237B (en) | 2015-06-12 | 2017-12-11 | Solid forms of (z) - 4 - (5 - ((3 - benzyl - 4 - oxo - 2 - thioxothiazolidine - 5 - ylidin) methyl) furan - 2 - yl) benzoic acid |
Country Status (12)
| Country | Link |
|---|---|
| US (4) | US10723726B2 (enExample) |
| EP (1) | EP3307722B1 (enExample) |
| JP (1) | JP2018521121A (enExample) |
| KR (1) | KR102663856B1 (enExample) |
| CN (1) | CN107848991B (enExample) |
| AU (2) | AU2016275125A1 (enExample) |
| BR (2) | BR112017026406A2 (enExample) |
| CA (2) | CA3221219A1 (enExample) |
| ES (1) | ES2896674T3 (enExample) |
| IL (1) | IL256237B (enExample) |
| SG (1) | SG10201911442XA (enExample) |
| WO (1) | WO2016201356A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3307722B1 (en) | 2015-06-12 | 2021-08-04 | GB006, Inc. | Solid forms of (z)-4-(5-((3-benzyl-4-oxo-2-thioxothiazolidin-5-ylidene)methyl)furan-2-yl)benzoic acid |
| US20200123146A1 (en) * | 2016-12-29 | 2020-04-23 | Gb006, Inc. | Heterocyclic integrin agonists |
| DK3601265T3 (da) * | 2017-03-30 | 2023-09-18 | Merck Patent Gmbh | Fast form af (s)-[2-chlor-4-fluor-5-(7-morpholin-4-ylquinazolin-4-yl)phenyl]-(6-methoxy-pyridazin-3-yl)methanol |
| TW202024061A (zh) | 2017-08-17 | 2020-07-01 | 美商基利科學股份有限公司 | Hiv蛋白質膜抑制劑之固體形式 |
| CA3103522C (en) | 2018-07-16 | 2023-11-21 | Gilead Sciences, Inc. | Capsid inhibitors for the treatment of hiv |
| EP3889136B1 (en) | 2018-11-28 | 2024-12-18 | Luoxin Pharmaceutical (Shanghai) Co., Ltd. | Salt form of estrogen receptor downregulator, crystalline form thereof, and preparation method therefor |
| WO2020236667A1 (en) * | 2019-05-17 | 2020-11-26 | Gb006, Inc. | Methods of treating cancer |
| WO2021061665A1 (en) * | 2019-09-23 | 2021-04-01 | Gb006, Inc. | Integrin agonist prodrugs |
| WO2021096988A1 (en) | 2019-11-12 | 2021-05-20 | Gb006, Inc. | Crystalline salt forms of (z)-4-(5-((3-benzyl-4-oxo-2-thioxothiazolidin-5-ylidene)methyl)furan-2-yl)benzoic acid |
| WO2023039170A1 (en) * | 2021-09-09 | 2023-03-16 | Musc Foundation For Research Development | Selective targeting of cd38 activity as an immunostimulatory and antitumor strategy |
| WO2024049275A1 (en) * | 2022-09-02 | 2024-03-07 | Rexpharmtech Co., Ltd | Novel benfotiamine choline salt |
| WO2024081449A1 (en) * | 2022-10-14 | 2024-04-18 | Rush University Medical Center | Cd11b agonists for treatment of autoimmune disease |
| CN121197154B (zh) * | 2025-11-13 | 2026-06-23 | 首都医科大学附属北京天坛医院 | Mac-1激动剂在制备治疗和/或缓解脑出血药物中的应用 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040002526A1 (en) * | 2002-04-03 | 2004-01-01 | Cell Therapeutics, Inc. | Phospholipase D inhibitors and uses thereof |
| US20120010255A1 (en) * | 2010-07-08 | 2012-01-12 | Vineet Gupta | Compounds and Methods for Regulating Integrins |
| WO2013159082A1 (en) * | 2012-04-20 | 2013-10-24 | Adhaere Pharmaceuticals, Inc. | Compounds and methods for regulating integrins |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1654380A4 (en) | 2003-08-14 | 2009-09-09 | Insight Biopharmaceuticals Ltd | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR MODULATING HEPARANASE ACTIVATION AND USES THEREOF |
| TW200526638A (en) * | 2003-10-22 | 2005-08-16 | Smithkline Beecham Corp | 2-(3,4-dimethylphenyl)-4-{[2-hydroxy-3'-(1H-tetrazol-5-yl)biphenyl-3-yl]-hydrazono}-5-methyl-2,4-dihydropyrazol-3-one choline |
| FI20041129A0 (fi) | 2004-08-30 | 2004-08-30 | Ctt Cancer Targeting Tech Oy | Tioksotiatsolidinoniyhdisteitä lääkkeinä käytettäviksi |
| US7718680B2 (en) * | 2004-09-23 | 2010-05-18 | Burnham Institute For Medical Research | Inhibition of lethal factor protease activity from anthrax toxin |
| ITMI20042475A1 (it) * | 2004-12-23 | 2005-03-23 | Cell Therapeutics Europe Srl | Uso di derivati tiazolidinonici come agenti terapeutici |
| WO2008005651A2 (en) * | 2006-06-08 | 2008-01-10 | Decode Chemistry, Inc. | Cyclic carboxylic acid rhodanine derivatives for the treatment and prevention of tuberculosis |
| WO2008082537A2 (en) | 2006-12-19 | 2008-07-10 | The General Hospital Corporation | Compounds for modulating integrin cd11b/cd18 |
| WO2008091532A1 (en) * | 2007-01-19 | 2008-07-31 | Panacos Pharmaceuticals, Inc. | Salts of 3-o-(3',3'-dimethylsuccinyl)betulinic acid and solid state forms thereof |
| CN103159695B (zh) * | 2011-12-08 | 2015-08-12 | 首都师范大学 | 可抑制hiv复制并对耐药hiv病毒株有效的噻唑类化合物及其制备方法和用途 |
| EP3307722B1 (en) | 2015-06-12 | 2021-08-04 | GB006, Inc. | Solid forms of (z)-4-(5-((3-benzyl-4-oxo-2-thioxothiazolidin-5-ylidene)methyl)furan-2-yl)benzoic acid |
-
2016
- 2016-06-10 EP EP16808465.5A patent/EP3307722B1/en active Active
- 2016-06-10 BR BR112017026406-4A patent/BR112017026406A2/pt not_active Application Discontinuation
- 2016-06-10 KR KR1020177037752A patent/KR102663856B1/ko active Active
- 2016-06-10 CA CA3221219A patent/CA3221219A1/en active Pending
- 2016-06-10 BR BR122023025347-7A patent/BR122023025347A2/pt not_active Application Discontinuation
- 2016-06-10 CN CN201680041800.5A patent/CN107848991B/zh active Active
- 2016-06-10 AU AU2016275125A patent/AU2016275125A1/en not_active Abandoned
- 2016-06-10 SG SG10201911442XA patent/SG10201911442XA/en unknown
- 2016-06-10 WO PCT/US2016/037067 patent/WO2016201356A1/en not_active Ceased
- 2016-06-10 ES ES16808465T patent/ES2896674T3/es active Active
- 2016-06-10 US US15/735,560 patent/US10723726B2/en active Active
- 2016-06-10 JP JP2018516398A patent/JP2018521121A/ja active Pending
- 2016-06-10 CA CA2988584A patent/CA2988584C/en active Active
-
2017
- 2017-12-11 IL IL256237A patent/IL256237B/en unknown
-
2019
- 2019-11-05 US US16/675,097 patent/US11111239B2/en active Active
-
2020
- 2020-11-16 AU AU2020270457A patent/AU2020270457B2/en active Active
-
2022
- 2022-11-01 US US17/978,848 patent/US12227497B2/en active Active
-
2025
- 2025-01-09 US US19/015,307 patent/US20250353840A1/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040002526A1 (en) * | 2002-04-03 | 2004-01-01 | Cell Therapeutics, Inc. | Phospholipase D inhibitors and uses thereof |
| US20120010255A1 (en) * | 2010-07-08 | 2012-01-12 | Vineet Gupta | Compounds and Methods for Regulating Integrins |
| WO2013159082A1 (en) * | 2012-04-20 | 2013-10-24 | Adhaere Pharmaceuticals, Inc. | Compounds and methods for regulating integrins |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2018521121A (ja) | 2018-08-02 |
| AU2016275125A1 (en) | 2018-01-25 |
| US10723726B2 (en) | 2020-07-28 |
| NZ738836A (en) | 2024-03-22 |
| EP3307722B1 (en) | 2021-08-04 |
| BR122023025347A2 (pt) | 2024-01-16 |
| AU2020270457A1 (en) | 2020-12-10 |
| US20180354938A1 (en) | 2018-12-13 |
| US20200317657A1 (en) | 2020-10-08 |
| CA2988584A1 (en) | 2016-12-15 |
| US12227497B2 (en) | 2025-02-18 |
| WO2016201356A1 (en) | 2016-12-15 |
| SG10201911442XA (en) | 2020-02-27 |
| KR102663856B1 (ko) | 2024-05-07 |
| CN107848991A (zh) | 2018-03-27 |
| US20250353840A1 (en) | 2025-11-20 |
| EP3307722A1 (en) | 2018-04-18 |
| ES2896674T3 (es) | 2022-02-25 |
| AU2020270457B2 (en) | 2022-10-20 |
| IL256237A (en) | 2018-02-28 |
| CN107848991B (zh) | 2022-01-14 |
| KR20180016443A (ko) | 2018-02-14 |
| US20230227443A1 (en) | 2023-07-20 |
| CA2988584C (en) | 2024-01-23 |
| CA3221219A1 (en) | 2016-12-15 |
| US11111239B2 (en) | 2021-09-07 |
| BR112017026406A2 (pt) | 2019-04-02 |
| EP3307722A4 (en) | 2018-12-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG10201911442XA (en) | Solid forms of (z)-4-(5-((3-benzyl-4-oxo-2-thioxothiazolidin-5-ylidene)methyl)furan-2-yl)benzoic acid | |
| IL259698B (en) | Crystalline 2- (3-ethanesulfonylfluoridine-2-yl)-5- (trifluoromethanesulfonyl)benzoxazole | |
| HUE047477T2 (hu) | Palbociclib szilárd dózisformái | |
| PL3371190T3 (pl) | Związki heterocykliczne jako inhibitory pi3k-gamma | |
| DK3351633T3 (da) | Antisense-nukleinsyre | |
| KR102254062B9 (ko) | 삼나트륨 발사르탄:사쿠비트릴의 고체 형태 | |
| IL257026A (en) | Solid state forms of eluxadoline | |
| ITUB20155853A1 (it) | Composizione di legante inorganico per colata | |
| EP2956428A4 (en) | FIRE-RESISTANT FUSION MOLDING MATERIAL WITH HIGH CIRCON OXIDE CONTENT | |
| SG11201707384YA (en) | Crystal of 3,5-disubstituted benzene alkynyl compound | |
| PL3107392T3 (pl) | Kompozycje grzybobójcze alkoksyamidów kwasu pirazolokarboksylowego | |
| HRP20181572T1 (hr) | Režim doziranja spoja fgf-18 | |
| SG11201507336WA (en) | Solid forms of 5-(halomethyl) furfural and methods for preparing thereof | |
| PL3107391T3 (pl) | Grzybobójcze kompozycje alkoksyamidów kwasów pirazolokarboksylowych | |
| IL254502A0 (en) | Solid forms of menaquinols | |
| DK3373931T3 (da) | Heterocykliske forbindelser til behandling af sygdom | |
| FI20150044A7 (fi) | Rasvahappokoostumus | |
| EP3319595A4 (en) | ENCAPSULATED ACTIVE SUBSTANCES FOR CONTROLLED ENTERAL ACTIVE COMPOSITION | |
| HUE064755T2 (hu) | Alfa-halo-akrilsav-származékok átmenetifém-katalizált protodekarboxilezõdése | |
| DK3389638T3 (da) | Farmaceutisk sammensætning omfattende pimobendan | |
| DK3280920T3 (da) | Reversibel forbindelse af maskinkomponenter | |
| EP3250540B8 (en) | Preparation of compounds from levulinic acid | |
| DK3283066T3 (da) | 4-Phenylsmørsyrederivater | |
| DK3581583T3 (da) | Farmaceutisk forbindelse | |
| IL253055B (en) | A method for the preparation of certain tetrazoles converted in positions 1 and 5 |